TITLE

Australia's National Bowel Cancer Screening Program: does it work for Indigenous Australians?

AUTHOR(S)
Christou, Aliki; Katzenellenbogen, Judith M; Thompson, Sandra C
PUB. DATE
January 2010
SOURCE
BMC Public Health;2010, Vol. 10, p373
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Despite a lower incidence of bowel cancer overall, Indigenous Australians are more likely to be diagnosed at an advanced stage when prognosis is poor. Bowel cancer screening is an effective means of reducing incidence and mortality from bowel cancer through early identification and prompt treatment. In 2006, Australia began rolling out a population-based National Bowel Cancer Screening Program (NBCSP) using the Faecal Occult Blood Test. Initial evaluation of the program revealed substantial disparities in bowel cancer screening uptake with Indigenous Australians significantly less likely to participate in screening than the non-Indigenous population. This paper critically reviews characteristics of the program which may contribute to the discrepancy in screening uptake, and includes an analysis of organisational, structural, and socio-cultural barriers that play a part in the poorer participation of Indigenous and other disadvantaged and minority groups. Methods: A search was undertaken of peer-reviewed journal articles, government reports, and other grey literature using electronic databases and citation snowballing. Articles were critically evaluated for relevance to themes that addressed the research questions. Results: The NBCSP is not reaching many Indigenous Australians in the target group, with factors contributing to sub-optimal participation including how participants are selected, the way the screening kit is distributed, the nature of the test and comprehensiveness of its contents, cultural perceptions of cancer and prevailing low levels of knowledge and awareness of bowel cancer and the importance of screening. Conclusions: Our findings suggest that the population-based approach to implementing bowel cancer screening to the Australian population unintentionally excludes vulnerable minorities, particularly Indigenous and other culturally and linguistically diverse groups. This potentially contributes to exacerbating the already widening disparities in cancer outcomes that exist among Indigenous Australians. Modifications to the program are recommended to facilitate access and participation by Indigenous and other minority populations. Further research is also needed to understand the needs and social and cultural sensitivities of these groups around cancer screening and inform alternative approaches to bowel cancer screening.
ACCESSION #
52840273

 

Related Articles

  • Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma with Concomitant Thyrotoxicosis: A Case Report and Literature Review. Chan, Jessie Y. W.; Tsui, David K. K.; Polly Tsui; Tang Chung Ngai // Surgical Science;Mar2014, Vol. 5 Issue 3, p117 

    Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPC) is a rare variant of conventional papillary thyroid carcinoma which was first reported in 1985. It appears to be more aggressive than conventional type of papillary thyroid carcinoma. We present a case in a 14-year-old girl who...

  • Prostate Cancer: An Evolving Paradigm. Caso, Jorge R.; Mouraviev, Vladimir; Tsivian, Matvey; Polascik, Thomas J.; Moul, Judd W. // Journal of Endourology;May2010, Vol. 24 Issue 5, p805 

    AbstractSince at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have...

  • MANAGEMENT OF UPPER GASTROINTESTINAL CANCERS: HOW ARE WE DOING?  // Gut;Apr2004 Supplement 3, Vol. 53, pA108 

    This article focuses on the management of upper gastrointestinal cancers by medical personnel. "NHS Cancer Plan" with earlier diagnosis and treatment of cancers is more so important in upper gastrointestinal (GI) cancers where the prognosis remains worse despite advances in treatment and hence a...

  • Outpatient Theraapy. Alexander, Walter // Dermatology Times;Jul2003, Vol. 24 Issue 7, p32 

    Focuses on the safety and efficacy of outpatient, self-administered chemobiotherapy for patients with metastatic melanoma in the U.S. Option for patients with metastatic melanoma; Design of the therapeutic method; Advantage of the method used in the prognosis of cancer patients.

  • New test improved prostate cancer risk assessment.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p8 

    The article reports that the genomic screening test called Oncotype DX has improved the ability to predict disease aggressiveness among patients at risk for prostate cancer.

  • Who cares about cancer? Ramos, Joana // New Internationalist;Nov2003, Issue 362, p24 

    Focuses on the diagnosis and treatment of cancer in the U.S. Details on the progression of the disease; Inadequacy of services offered to the patients; Improvements in the efforts of drug companies to develop the cure for cancer.

  • Overtreating earliest cancers -- but which ones? Neergaard, Lauran // Adirondack Daily Enterprise;6/19/2010, Vol. 117 Issue 144, pB6 

    The article focuses on the issue on the early detection of cancer tumors and how to treat them properly.

  • Erlotinib associated with increased OS, PFS in NSCLC with EGFR mutations.  // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p35 

    The article discusses research which found that screening patients with non-small cell lung cancer for epidermal growth factor receptor mutations for erlotinib therapy has led to improvement in median overall survival (OS) and progression-free survival (PFS).

  • Prostate cancer: 2. Natural history. Nam, Robert K.; Jewett, Michael A.S.; Krahn, Murray D. // CMAJ: Canadian Medical Association Journal;09/22/98, Vol. 159 Issue 6, p685 

    Presents the second in a 13-part series about the treatment of prostate cancer. Natural history of adenocarcinoma of the prostate; Effect of age and comorbidity on prognosis; Watchful waiting versus definitive treatment; Methods for assessing prognosis; Results of prognostic studies.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics